BRPI0817927A2 - Comprimidos orodispersiveis - Google Patents
Comprimidos orodispersiveisInfo
- Publication number
- BRPI0817927A2 BRPI0817927A2 BRPI0817927-1A BRPI0817927A BRPI0817927A2 BR PI0817927 A2 BRPI0817927 A2 BR PI0817927A2 BR PI0817927 A BRPI0817927 A BR PI0817927A BR PI0817927 A2 BRPI0817927 A2 BR PI0817927A2
- Authority
- BR
- Brazil
- Prior art keywords
- orodispersible
- pills
- orodispersible pills
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07380265 | 2007-10-01 | ||
US97716607P | 2007-10-03 | 2007-10-03 | |
PCT/EP2008/063068 WO2009043844A2 (en) | 2007-10-01 | 2008-09-30 | Orodispersible tablets |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0817927A2 true BRPI0817927A2 (pt) | 2015-04-07 |
Family
ID=38962587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0817927-1A BRPI0817927A2 (pt) | 2007-10-01 | 2008-09-30 | Comprimidos orodispersiveis |
Country Status (11)
Country | Link |
---|---|
US (3) | US9623010B2 (pt) |
EP (2) | EP2572705B1 (pt) |
JP (1) | JP2010540588A (pt) |
KR (1) | KR101626873B1 (pt) |
BR (1) | BRPI0817927A2 (pt) |
CA (1) | CA2703501C (pt) |
ES (1) | ES2645255T3 (pt) |
PL (1) | PL2572705T3 (pt) |
PT (1) | PT2572705T (pt) |
WO (1) | WO2009043844A2 (pt) |
ZA (1) | ZA201002255B (pt) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
AUPS088702A0 (en) * | 2002-03-04 | 2002-03-28 | Borody, Thomas Julius | Electrolyte purgative |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
EP2151235B1 (de) * | 2008-07-21 | 2011-02-16 | Dr. Falk Pharma Gmbh | Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes |
US8901113B2 (en) | 2009-09-30 | 2014-12-02 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
CN102114014A (zh) * | 2009-12-30 | 2011-07-06 | 北京德众万全药物技术开发有限公司 | 一种含有阿莫曲坦的药物组合物 |
US8906949B2 (en) * | 2010-05-21 | 2014-12-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablets of zolmitriptan and process for preparing the same |
FR2962331B1 (fr) * | 2010-07-06 | 2020-04-24 | Ethypharm | Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre |
WO2012014012A1 (es) * | 2010-07-27 | 2012-02-02 | Laboratorios Andrómaco S.A. | Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia. |
KR102216603B1 (ko) | 2010-08-04 | 2021-02-17 | 크레스토보 홀딩스 엘엘씨 | 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치 |
KR101947720B1 (ko) | 2010-12-13 | 2019-02-14 | 샐릭스 파마슈티컬스 인코포레이티드 | 위 및 결장 조제물 및 이의 제조 및 사용 방법 |
MX2013010343A (es) | 2011-03-09 | 2014-04-30 | Univ Minnesota | Composicion y metodos para el transplante de microbiota de colon. |
JP6208931B2 (ja) * | 2011-09-07 | 2017-10-04 | 三菱商事フードテック株式会社 | 硬度を高めた口腔内崩壊錠およびその製造方法 |
WO2013095314A1 (en) * | 2011-12-19 | 2013-06-27 | Mahmut Bilgic | Pharmaceutical formulations comprising risperidone |
WO2013100876A1 (en) * | 2011-12-27 | 2013-07-04 | Mahmut Bilgic | Risperidone formulations |
WO2013172805A1 (en) * | 2012-05-14 | 2013-11-21 | Mahmut Bilgic | New orodispersible tablet formulations of olanzapine |
WO2013175508A2 (en) | 2012-05-24 | 2013-11-28 | Medreich Limited | Stable pharmaceutical composition of aripiprazole |
WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
AU2013271336B2 (en) | 2012-06-04 | 2017-11-30 | Centre For Digestive Diseases | Compositions and methods for treating Crohn's Disease and related conditions and infections |
CA2880282C (en) | 2012-07-27 | 2020-09-01 | Redhill Biopharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
US9101636B2 (en) | 2012-11-30 | 2015-08-11 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
JP2016117651A (ja) * | 2013-04-16 | 2016-06-30 | 株式会社ダイセル | 小動物への投与に適した速崩壊錠とその簡便な製造方法 |
JP2016117652A (ja) * | 2013-04-16 | 2016-06-30 | 株式会社ダイセル | 小児への投与に適した速崩壊錠とその簡便な製造方法 |
US20160089363A1 (en) | 2013-04-30 | 2016-03-31 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
JP2014218472A (ja) * | 2013-05-10 | 2014-11-20 | エルメッド エーザイ株式会社 | オランザピン乃至その塩含有錠剤 |
JP5713421B1 (ja) | 2013-07-19 | 2015-05-07 | 株式会社三和化学研究所 | 口腔内崩壊錠 |
EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
WO2015045604A1 (ja) * | 2013-09-30 | 2015-04-02 | 富士フイルム株式会社 | 口腔内崩壊錠 |
WO2015067313A1 (en) * | 2013-11-07 | 2015-05-14 | Synthon B.V. | Orodispersible pharmaceutical compositions comprising aripiprazole |
EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
ES2716990T5 (es) | 2013-12-23 | 2023-03-24 | Dr Falk Pharma Gmbh | Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago |
WO2015145461A1 (en) | 2014-03-26 | 2015-10-01 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
CN114105851A (zh) | 2014-07-02 | 2022-03-01 | 奥布赛瓦股份公司 | 治疗ot-r活性相关的病症的方法中可用的晶体 |
AU2015287186B2 (en) | 2014-07-11 | 2018-05-31 | Azanta Danmark A/S | Misoprostol dispersible tablet |
US20160008310A1 (en) | 2014-07-11 | 2016-01-14 | Azanta A/S | Misoprostol dispersible tablet |
WO2016183577A1 (en) | 2015-05-14 | 2016-11-17 | Crestovo Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
NZ737786A (en) | 2015-05-22 | 2022-07-01 | Univ Minnesota | Methods for treating autism spectrum disorder and associated symptoms |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
WO2017053327A1 (en) | 2015-09-24 | 2017-03-30 | San Diego State University (Sdsu) Foundation , Dba San Diego State University Research Foundation | Antibacterial and protective bacteriophage formulations and methods for making and using them |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
JP2020513018A (ja) | 2017-04-05 | 2020-04-30 | クレストヴォ・ホールディングス・エルエルシー | パーキンソン病(pd)および関連する障害を治療するための組成物および方法 |
WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
JP2020530494A (ja) | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド. | 健康な腸バリアを維持及び回復するための組成物及び方法 |
US10288629B1 (en) * | 2017-12-19 | 2019-05-14 | Aeterna Zentaris, Inc. | Method of assessing growth hormone deficiency in humans by a macimorelin containing composition |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
AU2019351017A1 (en) | 2018-09-27 | 2021-04-29 | Finch Therapeutics Holdings Llc. | Compositions and methods for treating epilepsy and related disorders |
KR102084602B1 (ko) * | 2018-11-08 | 2020-03-04 | 주식회사 서흥 | 발포성 및 안정성이 향상된 구강 세정용 발포정 |
CA3116354A1 (en) | 2018-11-26 | 2020-06-04 | The Procter & Gamble Company | Solid pharmaceutical preparation containing lipoic acid and use thereof |
EP3766483A1 (en) * | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising a triptan |
CN110477378B (zh) * | 2019-08-02 | 2022-11-29 | 大连医诺生物股份有限公司 | 含脂溶性成分的口溶型直饮粉及其制备方法 |
CN112546002B (zh) * | 2020-12-07 | 2022-08-05 | 北京斯利安药业有限公司 | 一种生物素口崩片及其制备方法 |
KR102413426B1 (ko) | 2020-12-21 | 2022-06-29 | 주식회사 씨엠지제약 | 나라트립탄을 포함하는 구강용해 필름 제형 |
WO2024144678A1 (en) * | 2022-12-27 | 2024-07-04 | Atatürk Üni̇versi̇tesi̇ Fi̇kri̇ Mülki̇yet Haklari Koordi̇natörlüğü Döner Sermaye İşletmesi̇ | Orally disintegrating tablets (odt) formulations for the treatment of flu, common cold and allergic symptoms |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US6596311B1 (en) | 1998-03-06 | 2003-07-22 | Eurand International S.P.A. | Fast disintegrating tablets |
US20020071864A1 (en) * | 1999-03-25 | 2002-06-13 | Yuhan Corporation | Rapidly disintegrable tablet for oral administration |
US20030161879A1 (en) * | 1999-06-29 | 2003-08-28 | Shinji Ohmori | Tablets quickly disintegrating in mouth |
US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
US6583722B2 (en) | 2000-12-12 | 2003-06-24 | Kimberly-Clark Worldwide, Inc. | Wetness signaling device |
US6610266B2 (en) | 2001-11-28 | 2003-08-26 | Michael C. Withiam | Calcium metasilicates and methods for making |
EP1488811A1 (en) | 2002-03-06 | 2004-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Tablets quickly disintegrating in oral cavity |
US6984377B2 (en) * | 2002-05-29 | 2006-01-10 | J. M. Huber Corporation | Oral care products comprising calcium metasilicates |
ES2199061B1 (es) * | 2002-06-10 | 2005-02-16 | Laboratorios Vita, S.A. | Comprimidos bucodispersables y procedimiento para su obtencion. |
JP4726628B2 (ja) | 2003-10-15 | 2011-07-20 | 富士化学工業株式会社 | 口腔内速崩壊性錠剤 |
US20050244347A1 (en) * | 2004-04-30 | 2005-11-03 | Mehra Dev K | Oral care products comprising calcium phosphates |
ES2255429B1 (es) * | 2004-10-25 | 2007-08-16 | Italfarmaco, S.A. | Composiciones farmaceuticas bucodispersables. |
EP1681048A1 (en) | 2005-01-14 | 2006-07-19 | Krka Tovarna Zdravil, D.D., Novo Mesto | Orally disintegrating composition of olanzapine or donepezil |
DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
KR20140065482A (ko) * | 2005-03-24 | 2014-05-29 | 다이이찌 산쿄 가부시키가이샤 | 의약용 조성물 |
JP4944467B2 (ja) * | 2005-03-24 | 2012-05-30 | 第一三共株式会社 | 医薬用組成物 |
US20070202163A1 (en) * | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
US20090208576A1 (en) | 2006-03-31 | 2009-08-20 | Gandhi Anilkumar S | Orally Disintegrating Tablets |
EP1977734A1 (en) * | 2007-04-03 | 2008-10-08 | Royal College of Surgeons in Ireland | A method of producing fast dissolving tablets |
WO2009038145A1 (ja) | 2007-09-19 | 2009-03-26 | Asahi Breweries, Ltd. | 漢方エキス、生薬エキスあるいは天然物抽出エキスまたはそれらの混合物等の天然物由来物質を含有する顆粒物の製造方法およびその顆粒物から製造する錠剤の製造方法 |
-
2008
- 2008-09-30 EP EP12198042.9A patent/EP2572705B1/en active Active
- 2008-09-30 PL PL12198042T patent/PL2572705T3/pl unknown
- 2008-09-30 WO PCT/EP2008/063068 patent/WO2009043844A2/en active Application Filing
- 2008-09-30 BR BRPI0817927-1A patent/BRPI0817927A2/pt not_active Application Discontinuation
- 2008-09-30 CA CA2703501A patent/CA2703501C/en active Active
- 2008-09-30 JP JP2010527429A patent/JP2010540588A/ja active Pending
- 2008-09-30 KR KR1020107009611A patent/KR101626873B1/ko active IP Right Grant
- 2008-09-30 ES ES12198042.9T patent/ES2645255T3/es active Active
- 2008-09-30 US US12/680,296 patent/US9623010B2/en active Active
- 2008-09-30 PT PT121980429T patent/PT2572705T/pt unknown
- 2008-09-30 EP EP08804908A patent/EP2205213A2/en not_active Withdrawn
-
2010
- 2010-03-30 ZA ZA2010/02255A patent/ZA201002255B/en unknown
-
2016
- 2016-07-05 US US15/201,908 patent/US20160310470A1/en not_active Abandoned
-
2017
- 2017-02-16 US US15/434,772 patent/US20170157053A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2572705A1 (en) | 2013-03-27 |
KR20100077187A (ko) | 2010-07-07 |
WO2009043844A2 (en) | 2009-04-09 |
WO2009043844A3 (en) | 2009-06-18 |
US20170157053A1 (en) | 2017-06-08 |
PT2572705T (pt) | 2017-11-08 |
ZA201002255B (en) | 2011-12-28 |
PL2572705T3 (pl) | 2018-01-31 |
US9623010B2 (en) | 2017-04-18 |
JP2010540588A (ja) | 2010-12-24 |
KR101626873B1 (ko) | 2016-06-02 |
EP2205213A2 (en) | 2010-07-14 |
CA2703501C (en) | 2017-06-13 |
US20100297031A1 (en) | 2010-11-25 |
CA2703501A1 (en) | 2009-04-09 |
ES2645255T3 (es) | 2017-12-04 |
EP2572705B1 (en) | 2017-09-13 |
US20160310470A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0817927A2 (pt) | Comprimidos orodispersiveis | |
DK3090730T3 (da) | Tabletter omfattende eltrombopag-olamin | |
BRPI0920521A2 (pt) | combinação farmacêutica | |
BRPI0811269A2 (pt) | Adoçante | |
ATE501136T1 (de) | Imidazopyridinone | |
BRPI0810495A2 (pt) | difenil-di-hidro-imidazopiridinonas | |
BRPI0808889A2 (pt) | Comprimido desintegrante oral | |
BRPI0811451A2 (pt) | Exopolissacarídeo | |
BRPI0814519A2 (pt) | Organopolissiloxano | |
BRPI0812916A2 (pt) | Chupeta | |
BRPI0812840A2 (pt) | 2-imidazolinas | |
AT504327B8 (de) | Tablettenabfüllvorrichtung | |
AT505058A3 (de) | Türschliesssystem | |
DE112008001742A5 (de) | Sensoranordnung | |
BRPI0812994A2 (pt) | Microbiocidas | |
DK2272763T3 (da) | Blisterpakning-dispensermaskine | |
DK2007384T3 (da) | Orodispergerbare domperidontabletter | |
DE602007010950D1 (de) | Dosierpumpe | |
DE112008000345A5 (de) | Sensoranordnung | |
DE112008001216A5 (de) | Magnetronplasmaanlage | |
CU20090155A7 (es) | Macrolidos | |
DE102007038931A8 (de) | Fadenlagennähwirkstoffe | |
ES1064046Y (es) | Multiventuri dosificador | |
DK1970496T3 (da) | Doseringsarrangement | |
DE112008001534A5 (de) | Anreihgussform |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B07E | Notice of approval relating to section 229 industrial property law | ||
B06I | Technical and formal requirements: publication cancelled | ||
B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
B09B | Decision: refusal | ||
B09B | Decision: refusal |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |